Sensus Healthcare Gestione

Gestione criteri di controllo 3/4

Sensus Healthcare Il CEO è Joe Sardano, nominato in Jun2010, e ha un mandato di 14.42 anni. la retribuzione annua totale è $ 687.60K, composta da 65.4% di stipendio e 34.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 7.17% delle azioni della società, per un valore di € 8.14M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 7.8 anni.

Informazioni chiave

Joe Sardano

Amministratore delegato

US$687.6k

Compenso totale

Percentuale dello stipendio del CEO	65.4%
Mandato del CEO	14.4yrs
Proprietà del CEO	7.2%
Durata media del management	3.3yrs
Durata media del Consiglio di amministrazione	7.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Joe Sardano rispetto agli utili di Sensus Healthcare?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$7m
Mar 31 2024	n/a	n/a	US$5m
Dec 31 2023	US$688k	US$450k	US$485k
Sep 30 2023	n/a	n/a	-US$896k
Jun 30 2023	n/a	n/a	US$2m
Mar 31 2023	n/a	n/a	US$6m
Dec 31 2022	US$754k	US$400k	US$24m
Sep 30 2022	n/a	n/a	US$27m
Jun 30 2022	n/a	n/a	US$25m
Mar 31 2022	n/a	n/a	US$21m
Dec 31 2021	US$628k	US$375k	US$4m
Sep 30 2021	n/a	n/a	-US$181k
Jun 30 2021	n/a	n/a	-US$2m
Mar 31 2021	n/a	n/a	-US$4m
Dec 31 2020	US$510k	US$375k	-US$7m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	n/a	n/a	-US$3m
Dec 31 2019	US$467k	US$375k	-US$2m
Sep 30 2019	n/a	n/a	-US$3m
Jun 30 2019	n/a	n/a	-US$2m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$538k	US$360k	-US$2m
Sep 30 2018	n/a	n/a	-US$3m
Jun 30 2018	n/a	n/a	-US$3m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	US$490k	US$324k	-US$4m

Compensazione vs Mercato: La retribuzione totale di Joe ($USD 687.60K ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 473.78K ).

Compensazione vs guadagni: La retribuzione di Joe è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Joe Sardano (71 yo)

14.4yrs

Mandato

US$687,599

Compensazione

Mr. Joseph C. Sardano, also known as Joe, serves as Director at BioFlorida Inc since August 2021. He Co-Founded Sensus Healthcare, Inc. in 2010 and has been its Chairman of the Board, Chief Executive Offic...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joseph Sardano	Co-Founder	14.4yrs	US$687.60k	7.17% € 8.1m
Michael Sardano	President	7.8yrs	US$452.53k	0.46% € 518.2k
Javier Rampolla	Chief Financial Officer	4.8yrs	US$357.06k	0.25% € 278.7k
Magdalena Martinez	Chief Operating Officer	1.8yrs	Nessun dato	0.060% € 67.6k
Emiliano Sosa	Chief Technology Officer	1.8yrs	Nessun dato	0.061% € 69.3k
Stephanie Tipton	Vice President of Marketing	1.8yrs	Nessun dato	Nessun dato

3.3yrs

Durata media

46yo

Età media

Gestione esperta: Il team dirigenziale di 5TX è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Joseph Sardano	Co-Founder	14.4yrs	US$687.60k	7.17% € 8.1m
Michael Sardano	President	less than a year	US$452.53k	0.46% € 518.2k
Anthony Petrelli	Independent Director	8.3yrs	US$75.00k	0.28% € 321.8k
Brian Berman	Member of Medical Advisory Board	7.8yrs	Nessun dato	Nessun dato
Angela Abbatecola	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
David Goldberg	Member of Medical Advisory Board	7.8yrs	Nessun dato	Nessun dato
Kevin Schewe	Member of Medical Advisory Board	7.8yrs	Nessun dato	Nessun dato
William McCall	Independent Director	9.1yrs	US$75.00k	0.061% € 69.3k
William Roth	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Robert Beer	Member of Medical Advisory Board	7yrs	Nessun dato	Nessun dato
Michael Gold	Member of the Medical Advisory Board	no data	Nessun dato	Nessun dato
Kenrick Spence	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato

7.8yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 5TX sono considerati esperti (durata media dell'incarico 7.8 anni).

Sensus Healthcare Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director recently sold €114k worth of stock

Sensus Healthcare, Inc., Annual General Meeting, May 31, 2024

Sensus Healthcare Announces Directors Changes

Sensus Healthcare, Inc. Appoints Michael Sardano as A Director, Effective February 1, 2024

Independent Director recently bought €55k worth of stock

Sensus Healthcare, Inc. Announces Senior Management Appointments and Promotions

Recent updates

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Second quarter 2024 earnings released: EPS: US$0.099 (vs US$0.023 loss in 2Q 2023)

Investor sentiment improves as stock rises 15%

Independent Director recently sold €114k worth of stock

Investor sentiment improves as stock rises 38%

First quarter 2024 earnings released: EPS: US$0.14 (vs US$0.12 loss in 1Q 2023)

Sensus Healthcare, Inc., Annual General Meeting, May 31, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$1.47 in FY 2022)

Full year 2023 earnings released: EPS: US$0.03 (vs US$1.47 in FY 2022)

Sensus Healthcare Announces Directors Changes

New major risk - Share price stability

Sensus Healthcare, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Sensus Healthcare, Inc. Appoints Michael Sardano as A Director, Effective February 1, 2024

Third quarter 2023 earnings released: US$0.089 loss per share (vs US$0.11 profit in 3Q 2022)

Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego

New major risk - Earnings quality

Investor sentiment improves as stock rises 36%

Sensus Healthcare, Inc. (NasdaqCM:SRTS) announces an Equity Buyback for $3 million worth of its shares.

Second quarter 2023 earnings released: US$0.023 loss per share (vs US$0.21 profit in 2Q 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 15%

Independent Director recently bought €55k worth of stock

Investor sentiment deteriorates as stock falls 36%

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.97 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$1.47 (vs US$0.25 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Now 21% undervalued

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: US$1.47 (vs US$0.25 in FY 2021)

Sensus Healthcare, Inc. Announces Senior Management Appointments and Promotions

Investor sentiment improved over the past week

Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sensus Healthcare, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.012 in 3Q 2021)

Investor sentiment deteriorated over the past week

Sensus Healthcare, Inc. Introduces Silk(TM) Laser Hair Removal System

Co-Founder recently sold €524k worth of stock

Sensus Healthcare, Inc. Appoints Mohammad K. Khan to Medical Advisory Board

Investor sentiment improved over the past week

Independent Director recently sold €686k worth of stock

Sensus Healthcare, Inc. Launches Upgrade to its SRT-100 Vision System with New Ultrasound Capabilities

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.017 loss in 2Q 2021)

Investor sentiment improved over the past week

Independent Director recently sold €72k worth of stock

First quarter 2022 earnings released: EPS: US$0.97 (vs US$0.068 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: EPS: US$0.25 (vs US$0.42 loss in FY 2020)

Investor sentiment improved over the past week

Co-Founder recently sold €1.2m worth of stock

Empyrean Medical System Inc. acquired Sculptura Assets of Sensus Healthcare, Inc. for $15 million.

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sensus Healthcare, Inc. Announces Three Promotions

Sensus Healthcare, Inc. Announces Executive Changes

Now 20% undervalued

Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter of 2021

Forecast breakeven date moved forward to 2021

Sensus Healthcare, Inc. Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia

Third quarter 2021 earnings released: EPS US$0.012 (vs US$0.10 loss in 3Q 2020)

Forecast to breakeven in 2022

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.16 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.068 loss per share (vs US$0.22 loss in 1Q 2020)

Colorado State University, Flint Animal Cancer Center Applies Sensus Healthcare’s SRT Non-Surgical Treatment to Animal Care

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.10 loss in FY 2019)

Revenue beats expectations

New 90-day high: €3.55